Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gower Publishing

Striving to become more patient-centric?

Explore more with OPEN Health

OPEN Health

Consumer health specialist joins Research Partnership Inc

Global healthcare market research consultancy Research Partnership has appointed Jennifer Stewart as a Director in their US offices in Philadelphia.

Inizio

White paper helps industry navigate new NHS roadmap

New report shows how pharma can support the NHS in the Covid-19 recovery era

Wilmington Healthcare

- PMLiVE

COVID-19 vaccine ‘unlikely’ to be available this year, says UK’s chief medical officer

Chris Whitty warns that there is no certainty that an effective vaccine will be available before winter 2021

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

Audentes’ rare disease gene therapy programme delayed after third patient death

Third patient death caused by gastrointestinal bleeding

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

Meet OPEN Health and Pharmerit Experts at the World Orphan Drug Virtual USA Congress

Join OPEN Health and Pharmerit – an OPEN Health Company at the World Orphan Drug Virtual Congress from August 24-27, 2020, as we present:Advanced Therapies Commercial: Tuesday, August 25Succeeding with Star Wars...

OPEN Health

- PMLiVE

We need to keep learning to keep innovating

How embracing experimentation and making space for learning can fuel creativity

- PMLiVE

Keytruda improves survival in first-line oesophageal cancer

Topline data demonstrates promising efficacy in the first-line setting

- PMLiVE

Janssen scores another expansion for new Darzalex combination in the US

Myeloma med approved in combination with Amgen's Kyprolis

- PMLiVE

Novartis wins FDA approval for relapsing MS drug Kesimpta

Swiss pharma company is expecting EU approval for treatment next year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links